mTORC1信号传递和糖尿病病
Vinamra Swaroop1, Eden Ozkan1, Lydia Herrmann1
1Life Sciences Institute, University of Michigan, Ann Arbor, USA.
Diabetology international
|October 29, 2024
概括
糖尿病病 (DKD) 是一种严重的糖尿病并发症. 针对mTORC1通路提供了一个有前途的新治疗策略,用于预防和治疗DKD.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學.
- 内分泌学 在内分泌学.
- 分子生物学分子生物学
背景情况:
- 糖尿病病 (DKD) 是糖尿病患者死亡的主要原因.
- DKD通常无症状地进展,一旦出现症状,就很难治疗.
- 目前的治疗方法,如SGLT2抑制剂和ARBs具有局限性,需要新的方法.
研究的目的:
- 审查RAPAMYCIN复合体1 (mTORC1) 信号通路的机械性标在DKD病变发生过程中的作用.
- 探索mTORC1作为DKD和其他慢性脏疾病 (CKD) 的潜在治疗点.
主要方法:
- 对糖尿病和脏疾病中mTORC1信号传递研究的文献综述.
- 对将代谢和血液动力学变化与DKD联系起来的分子机制的分析.
- 讨论针对mTORC1.1.的现有和潜在的治疗策略.
主要成果:
- mTORC1通路通过营养感应和细胞过程调节,与DKD发育有关.
- mTORC1的失调有助于DKD的代谢和信号改变.
- 针对mTORC1可能为DKD提供新的治疗途径.
结论:
- mTORC1通路是DKD病变发生的关键调节者.
- 抑制或调节mTORC1信号传递为未来的DKD疗法提供了一个有希望的策略.
- 对糖尿病和慢性病的mTORC1向治疗进行进一步的研究是有必要的.
更多相关视频
08:15Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
Published on: May 10, 2024
504
07:15Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
348
相关概念视频
03:03mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
01:22PI3K/mTOR/AKT Signaling Pathway
3.4K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.4K